HKG:1099 31 January 2026

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.

31 January 2026

HKG:1099·NYSE:AZN·NYSE:LLY·NYSE:MRK·NYSE:NVO·NYSE:PFE·Pharmaceuticals

Appen Limited (APX.AX) Trades at A$1.69 Amid AI Data Demand and Financial Resilience
March 14, 2026, 1:09 AM EDT. Appen Limited (APX.AX) stock trades intraday at A$1.69 on the ASX, rising 1.20%, driven by AI market demand and recent financial results. The company, specializing in data labeling for AI models, shows a net cash position of A$75.59 million and positive free cash flow of A$28.39 million over the past year. Intraday volume is below average, with momentum indicators signaling mild strength. Valuation metrics reveal a market cap of A$452.95 million and a trailing negative PE of -14.08, reflecting ongoing profitability challenges despite solid balance sheet metrics. Analysts rate APX.AX as a HOLD with potential upside from AI training budgets and contract renewals, yet risks include negative margins and an elevated bankruptcy risk per its Altman Z-Score.